Showing 1961-1970 of 3134 results for "".
- AAD 2026: RelabotulinumtoxinA Shows Consistent Efficacy Across Age Groupshttps://modernaesthetics.com/news/aad-2026-relabotulinumtoxina-shows-consistent-efficacy-across-age-groups/2486431/A post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated the impact of age on outcomes with relabotulinumtoxinA in patients with moderate-to-severe glabellar lines (GLs) and lateral canthal lines (LCLs). The analysis pooled data
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://modernaesthetics.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- AAD 2026: Oral Supplement Shows Gains in Hair Strength, Collagen VIIhttps://modernaesthetics.com/news/aad-2026-oral-supplement-shows-gains-in-hair-strength-collagen-vii/2486396/New data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated a nutraceutical approach to improving hair strength through collagen VII upregulation and mechanical resistance outcomes. The study assessed a daily oral supplement containing turmer
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- FDA Clears Full-Wavelength Capability for Lasermach Laser Systemhttps://modernaesthetics.com/news/fda-clears-full-wavelength-capability-for-lasermach-laser-system/2486382/Wingderm announced that its Lasermach laser system has received expanded clearance from the US Food and Drug Administration (FDA), enabling use across all 3 wavelengths—755 nm, 808 nm, and 1064 nm. The update includes clearance for a mixed-wavelength handpiece combining all 3 wavelengths, as well
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://modernaesthetics.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://modernaesthetics.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://modernaesthetics.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A
- LaserAway Introduces Three New Services Across Its Clinic Networkhttps://modernaesthetics.com/news/laseraway-introduces-three-new-services-across-its-clinic-network/2486088/LaserAway announced the launch of 3 new services across its clinic network: the Salmon DNA Facial, XTherma, and an expanded portfolio of LaserAway Wellness Injections. The company said the additions reflect continued investment in science-backed treatments and its medical-first approach to expand
- Survey: 53% of Americans Would Sacrifice Everyday Spending for Aesthetic Treatmentshttps://modernaesthetics.com/news/survey-53-of-americans-would-sacrifice-everyday-spending-for-aesthetic-treatments/2486047/More than half of Americans say they would sacrifice everyday spending to afford non-surgical aesthetic procedures, according to a new national survey commissioned by LaserAway and conducted by Morning Consult among 2,202 US adults in February 2026. The findings highlight shifting consumer attitu